StartupHub Opportunity: Safe Lactobacillus Biologic for C. difficile Resistance & Vaccine скачать в хорошем качестве

StartupHub Opportunity: Safe Lactobacillus Biologic for C. difficile Resistance & Vaccine

Innovations in microbiome-based therapeutics are transforming how we prevent and treat Clostridioides difficile infection (CDI). This safe, Lactobacillus-based synthetic biologic is designed to establish colonization resistance by preventing C. difficile from attaching to the gastrointestinal tract, while also functioning as an oral vaccine to stimulate protective immunity. By leveraging a naturally occurring gut bacterium engineered for precision targeting, this technology offers a microbiome-sparing alternative to traditional antibiotics and includes built-in safety features such as a self-limiting kill switch. In preclinical studies, the platform demonstrated strong efficacy and tolerability, highlighting its potential to prevent recurrent infections and improve patient outcomes. Join us in advancing next-generation biologic therapies that provide safer, more effective protection against serious gastrointestinal infections. This opportunity features Gayatri Vedantam, PhD, Professor, School of Animal and Comparative Biomedical Sciences at the College of Agriculture, Life and Environmental Sciences at the University of Arizona, inventor and scientific lead behind the technology. View this and other high-potential technologies on the Tech Launch Arizona StartupHub.